Machinery / Industrial Parts & Tools

Recently, OrbusNeich Medical Group Limited (OrbusNeich Medical Group Limited), the world's leading vascular interventional device company, announced that it has received approximately US$200 million in financing. This round of financing was led by Shenzhen Venture Capital and its Hongtu Medical Fund, followed by CCB International, Galaxy Capital, Wanhui Capital, and China Merchants Securities Investment.

Yikai Capital and CITIC Securities acted as financial advisors to Yeju Medical in this transaction.

This round of financing follows the tens of millions of dollars in Series A financing completed by Yeju Medical not long ago. The A round of financing was jointly led by CICC Kai Tak Fund and China Merchants Securities Investment, a subsidiary of CICC Capital, and shared the investment and followed the investment. The completion of two consecutive rounds of financing fully reflects the high recognition of professional investment institutions for the future development potential of Yeju Medical.

Yeju Medical said that this round of financing will accelerate the company's continuous research and development of various new products, and promote the further expansion of the existing group's business in Greater China and even the world.

Yeju Medical is headquartered in Hong Kong, China. It is a globalized vascular interventional medical device innovation enterprise. It has production and R&D bases in China, the Netherlands and the United States, and branches all over the world. The company’s vascular interventional products include catheters for coronary and peripheral vascular interventions, balloon dilatation catheters, scoring balloons and innovative coated stents, as well as neurointerventional balloons and heart valves from a joint venture of Yeju Medical Waiting for multiple blockbuster products in research. Over the years, Yeju Medical's products have been sold to dozens of countries around the world, and have accumulated a good reputation at home and abroad, and won unanimous praise from clinical experts around the world.

Mr. Qian Yongxun, CEO of Yeju Medical, said: “Yeju Medical has been committed to the research and development of innovative vascular interventional medical devices since its establishment. This financing has won the strong support of investors and partners, and we will continue to increase innovation and research and development. , To manufacture better and more comprehensive products. Yeju Medical has a professional and dedicated R&D team, world-class production technology and mature global sales system, which will continue to benefit patients with cardiovascular diseases around the world."

Zhou Yi, General Manager of Shenzhen Venture Capital Hongtu Medical Fund, said: “Yeju Medical is a cardiovascular interventional device company with a global layout. Yeju Medical has been competing with international giants in overseas markets for many years. Value consumables companies are very rare. Shenzhen Venture Capital and Hongtu Medical Fund firmly support Yeju Medical and achieve greater breakthroughs in existing businesses and future innovative products."

Liang Ying, Managing Director of CICC Qide Fund, said: “Yeju Medical is an excellent vascular interventional national enterprise with global competitiveness. The management team has a global vision and international operation capabilities, leading the company to root in China and integrate into the world. After 20 years of painstaking efforts, the company's products have won an excellent reputation in the industry, sold all over the world, and have a leading market share in developed markets such as Japan and Europe. At the same time, the company has invested heavily in research and development, and has the world's leading pre-loaded dry valve, Advanced technologies such as the second-generation antibody coating and innovative drug-carrying balloons. We believe that under the leadership of an excellent management team, the company will develop rapidly and with high quality."

Zhan Guifeng, General Manager of China Merchants Securities Investment, said: “Yeju Medical’s product pipeline has achieved full coverage of cardiovascular interventional treatments. It has products on the market for coronary intervention and peripheral intervention, and is deploying in the fields of neuro intervention and structural heart disease. The medical team has a global vision, actively researches and develops global innovative products, and continuously introduces international innovative products into the country. We continue to be optimistic about the company's sales expansion in the domestic market."

Mr. Huang Fangzhi, co-founder of Sharing Investment and managing partner of Sharing Investment Medical and Health Fund, said: “The vascular interventional device industry has developed rapidly in the past few years. In recent years, the industry’s import substitution has accelerated significantly. Master a number of core technologies, and have layout and expansion plans in the fields of functional balloons, innovative drug-loaded balloons, and neurointerventional consumables. The matrix of vascular interventional products is becoming more and more complete and the categories are complete. It has a good market in developed countries in Europe, America and Japan. The market foundation and brand influence of the company, the pre-loaded dry valve technology that the company has mastered, has huge room for future development. We are very pleased to have the opportunity to work with Yeju to further promote the application and development of innovative vascular interventional products in actual clinical practice."

Li Gang, a partner of Yikai Capital and co-head of the health industry, said: “Yeju Medical is the first national brand of high-level vascular interventional therapy devices to achieve a global layout. We are very honored to help companies complete this round of financing. I look forward to the company's future milestone development, and we will continue to move forward hand in hand on the way to grow into a leading company in the global vascular intervention and structural heart field."